港股异动 | 科伦博泰生物-B(06990)涨超6% 核心产品sac-TMT顺利获批上市默沙东快速推进全球3期临床

智通财经2025-04-14

智通财经APP获悉，科伦博泰生物-B(06990)涨超6%，截至发稿，涨5.5%，报318.2港元，成交额8556.28万港元。国信证券发布研报称，科伦博泰生物-B的核心产品sac-TMT/SKB264(TROP2 ADC)的第一和第二个适应症(TNBC 3L 和EGFRmNSCLC 3L)分别在24年底和25年初获批上市，成为首个获批肺癌适应症的TROP2 ADC。EGFRm NSCLC 2L...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2527942747?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-04-14 10:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2527942747","market":"us","top_or_hot":-1,"title":"港股异动 | 科伦博泰生物-B(06990)涨超6% 核心产品sac-TMT顺利获批上市 默沙东快速推进全球3期临床","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，科伦博泰生物-B(06990)涨超6%，截至发稿，涨5.5%，报318.2港元，成交额8556.28万港元。国信证券发布研报称，科伦博泰生物-B的核心产品sac-TMT/SKB264(TROP2 ADC)的第一和第二个适应症(TNBC 3L 和EGFRmNSCLC 3L)分别在24年底和25年初获批上市，成为首个获批肺癌适应症的TROP2 ADC。EGFRm NSCLC 2L...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1277957.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股异动 | 科伦博泰生物-B(06990)涨超6% 核心产品sac-TMT顺利获批上市 默沙东快速推进全球3期临床</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股异动 | 科伦博泰生物-B(06990)涨超6% 核心产品sac-TMT顺利获批上市 默沙东快速推进全球3期临床\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-04-14 10:31 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1277957.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，科伦博泰生物-B(06990)涨超6%，截至发稿，涨5.5%，报318.2港元，成交额8556.28万港元。国信证券发布研报称，科伦博泰生物-B的核心产品sac-TMT/SKB264(TROP2 ADC)的第一和第二个适应症(TNBC 3L 和EGFRmNSCLC 3L)分别在24年底和25年初获批上市，成为首个获批肺癌适应症的TROP2 ADC。EGFRm NSCLC 2L...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1277957.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00B1BXHZ80.USD","symbol_name":"Legg Mason ClearBridge - US Appreciation A Acc USD","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1277957.html","article_id":"2527942747","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2527942747","pubTimestamp":1744597910,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"国信证券发布研报称，科伦博泰生物-B的核心产品sac-TMT/SKB264的第一和第二个适应症分别在24年底和25年初获批上市，成为首个获批肺癌适应症的TROP2 ADC。EGFRm NSCLC 2L适应症的上市申请已经获得受理，预计将在今年获批上市，EGFRm NSCLC 1L、驱动基因阴性NSCLC 1L、TNBC1L等适应症正在进行3期临床。合作伙伴默沙东已经开启了12项sac-TMT的全球多中心3期临床，涵盖了肺癌、乳腺癌、妇科肿瘤等多适应症。随着sac-TMT、塔戈利单抗和西妥昔单抗N01相继获批上市，公司正式进入商业化阶段。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","LU0122379950.USD":"贝莱德世界健康科学A2","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","BK4516":"特朗普概念","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","LU0070302665.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) ACC","LU0965509010.AUD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (AUDHDG) INC","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","LU0320765489.SGD":"FTIF - Franklin Mutual US Value A Acc SGD","LU1989772840.SGD":"CPR Invest - Climate Action A2 Acc SGD-H","BK4550":"红杉资本持仓","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","LU0006306889.USD":"SCHRODER ISF US LARGE CAP \"A\" (USD) INC AV","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","LU1037948897.HKD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (HKD) INC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","SG9999014567.USD":"UOB UNITED INCOME FOCUS TRUST FUND (USD) ACC","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","LU0196878994.USD":"MANULIFE GF CHINA VALUE \"AA\" (USD) INC","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","LU1934455277.USD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"AD\" (USD) INC","LU0265550359.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A2\" (USD) ACC","LU2023250843.SGD":"Allianz Thematica Cl AT Acc H2-SGD","BK4007":"制药","LU1917777945.USD":"安联专题基金Cl AT Acc","SG9999014575.USD":"UOB UNITED INCOME FOCUS TRUST FUND (USDHDG) INC","LU1037948541.HKD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"A\" (HKD) ACC","SG9999002232.USD":"Allianz Global High Payout USD","LU0985320562.USD":"NORDEA 1 GLOBAL STARS EQUITY \"BP\" (USD) ACC","SG9999015358.SGD":"United Income Focus Trust Dis SGD-H","BK1161":"生物科技","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU1116320737.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A6\" (USD) INC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU2361044949.HKD":"WELLINGTON US QUALITY GROWTH \"A\" (HKD) ACC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","MRK":"默沙东","LU2106854487.HKD":"ALLIANZ THEMATICA \"AMG\" (HKD) INC","BK4585":"ETF&股票定投概念","LU2361044865.SGD":"WELLINGTON US QUALITY GROWTH \"A\" (SGDHDG) ACC","06990":"科伦博泰生物-B","LU1162221912.USD":"FRANKLIN INCOME \"A\" (USD) ACC","BK4533":"AQR资本管理(全球第二大对冲基金)","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC"},"translate_title":"Changes in Hong Kong stocks Kelun Botai Biotech-B (06990) rose more than 6%, core product sac-TMT was successfully approved for listing, Merck rapidly advances global phase 3 clinical trials","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRK":1,"06990":1},"content_text":"智通财经APP获悉，科伦博泰生物-B(06990)涨超6%，截至发稿，涨5.5%，报318.2港元，成交额8556.28万港元。国信证券发布研报称，科伦博泰生物-B的核心产品sac-TMT/SKB264(TROP2 ADC)的第一和第二个适应症(TNBC 3L 和EGFRmNSCLC 3L)分别在24年底和25年初获批上市，成为首个获批肺癌适应症的TROP2 ADC。EGFRm NSCLC 2L适应症的上市申请已经获得受理，预计将在今年获批上市，EGFRm NSCLC 1L、驱动基因阴性NSCLC 1L、TNBC1L等适应症正在进行3期临床。合作伙伴默沙东已经开启了12项sac-TMT的全球多中心3期临床，涵盖了肺癌、乳腺癌、妇科肿瘤等多适应症。该行续指， 公司2024年营收为19.33亿元(+25.5%)，营收主要来自合作收入，研发费用为12.06亿元(+17.0%)，全年亏损2.67亿元(上年同期亏损5.74亿元)。截至24年底，公司在手现金及金融资产约30.8亿元(+21.5%)。随着sac-TMT、塔戈利单抗和西妥昔单抗N01相继获批上市，公司正式进入商业化阶段。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease,movement","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2527942747","isCrawlerRequest":true}

港股异动 | 科伦博泰生物-B(06990)涨超6% 核心产品sac-TMT顺利获批上市 默沙东快速推进全球3期临床

精彩评论

港股异动 | 科伦博泰生物-B(06990)涨超6% 核心产品sac-TMT顺利获批上市默沙东快速推进全球3期临床